| 1 |
34567247 | Retrospective analysis of the role of cyclin E1 overexpression as a predictive marker for the efficacy of bevacizumab in platinum-sensitive recurrent ovarian cancer. | 2021 |
2 |
| 2 |
34622231 | CCNE1 copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer models. | 2021 Sep 21 |
1 |
| 3 |
32709856 | Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models. | 2020 Jul 24 |
1 |
| 4 |
31060523 | Genomic profiling in ovarian cancer retreated with platinum based chemotherapy presented homologous recombination deficiency and copy number imbalances of CCNE1 and RB1 genes. | 2019 May 6 |
3 |
| 5 |
29724815 | Biomarker Assessment of HR Deficiency, Tumor BRCA1/2 Mutations, and CCNE1 Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following Platinum Monotherapy. | 2018 Jul |
1 |
| 6 |
28977941 | CCNE1 expression in high grade serous carcinoma does not correlate with chemoresistance. | 2017 Sep 22 |
2 |
| 7 |
26693899 | Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer. | 2016 Jan |
2 |
| 8 |
24560445 | Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts. | 2014 May |
1 |
| 9 |
24218601 | Synthetic lethality between CCNE1 amplification and loss of BRCA1. | 2013 Nov 26 |
1 |